explore -WSS

explore

author：hotspot 2025-09-30 19:27:01 - browse：8548

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. — Novo Nordisk via AP

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss.

The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%. That finding, which was the primary outcome the trial set out to study, was stronger than many were expecting and led Novo’s stock to surge.

But details of the study, including risk reductions for each specific heart complication, were not released until Saturday, when they were presented here — before a standing-room only crowd — as the first major session of the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Congress likely to miss an opportunity to fix drug shortages issue

WSS

Celiac disease study examines precisely how gluten triggers injury

Europe sees delivery challenges ahead on Alzheimer's therapies

Steward Health Care Massachusetts hospitals face fiscal disaster

Eli Lilly to acquire Versanis in heated race for weight loss drugs

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

UCLA team creates talking throat patch for voice disorders

focus

explore

explore

In age of alternative facts, a scholarly course on calling out crap

HHS secretary Becerra pressed on Change HealthCare cyberattack

In age of alternative facts, a scholarly course on calling out crap

Celiac disease study examines precisely how gluten triggers injury

At least 13 dead in Texas as scorching temps continue

Congress: Eradicate hepatitis C and reduce the deficit

At least 13 dead in Texas as scorching temps continue

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Trump demands the U.S. pay no more for drugs than other countries … again

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

focus

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

The new HIV moral panic

Why police arrested suspected Gilgo Beach killer away from his house

Change Healthcare outage fallout shows need for new oversight

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

As AI in medicine takes off, can 'human in the loop' prevent harm?

focus

leisure time

knowledge

Wikipedia